NASDAQ:CPRX - Catalyst Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Catalyst Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $4.66 +0.13 (+2.87 %) (As of 02/26/2020 04:00 PM ET) Add Compare Today's Range$4.44Now: $4.66▼$4.8150-Day Range$3.98MA: $4.46▼$5.2152-Week Range$2.23Now: $4.66▼$7.67Volume2.39 million shsAverage Volume1.96 million shsMarket Capitalization$480.20 millionP/E Ratio58.26Dividend YieldN/ABeta2.47 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome in the United States. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CPRX Previous Symbol CUSIPN/A CIK1369568 Webhttp://www.catalystpharma.com/ Phone305-420-3200Debt Debt-to-Equity Ratio0.01 Current Ratio5.04 Quick Ratio5.00Price-To-Earnings Trailing P/E Ratio58.26 Forward P/E Ratio14.12 P/E GrowthN/A Sales & Book Value Annual Sales$500,000.00 Price / Sales960.40 Cash FlowN/A Price / Cash FlowN/A Book Value$0.49 per share Price / Book9.51Profitability EPS (Most Recent Fiscal Year)($0.33) Net Income$-34,000,000.00 Net Margins12.99% Return on Equity15.53% Return on Assets12.74%Miscellaneous Employees51 Outstanding Shares103,047,000Market Cap$480.20 million Next Earnings Date3/16/2020 (Estimated) OptionableOptionable Receive CPRX News and Ratings via Email Sign-up to receive the latest news and ratings for CPRX and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:CPRX Rates by TradingView Catalyst Pharmaceuticals (NASDAQ:CPRX) Frequently Asked Questions What is Catalyst Pharmaceuticals' stock symbol? Catalyst Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPRX." How were Catalyst Pharmaceuticals' earnings last quarter? Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) announced its quarterly earnings data on Tuesday, November, 12th. The biopharmaceutical company reported $0.13 EPS for the quarter, topping analysts' consensus estimates of $0.11 by $0.02. The biopharmaceutical company earned $30.90 million during the quarter, compared to analysts' expectations of $33.19 million. Catalyst Pharmaceuticals had a return on equity of 15.53% and a net margin of 12.99%. View Catalyst Pharmaceuticals' Earnings History. When is Catalyst Pharmaceuticals' next earnings date? Catalyst Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Catalyst Pharmaceuticals. What guidance has Catalyst Pharmaceuticals issued on next quarter's earnings? Catalyst Pharmaceuticals updated its FY 2020 Pre-Market earnings guidance on Monday, January, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $135-155 million, compared to the consensus revenue estimate of $145.62 million. What price target have analysts set for CPRX? 4 brokerages have issued 1 year price objectives for Catalyst Pharmaceuticals' shares. Their forecasts range from $7.00 to $12.00. On average, they expect Catalyst Pharmaceuticals' stock price to reach $9.75 in the next year. This suggests a possible upside of 109.2% from the stock's current price. View Analyst Price Targets for Catalyst Pharmaceuticals. What is the consensus analysts' recommendation for Catalyst Pharmaceuticals? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalyst Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Catalyst Pharmaceuticals. What are Wall Street analysts saying about Catalyst Pharmaceuticals stock? Here are some recent quotes from research analysts about Catalyst Pharmaceuticals stock: 1. According to Zacks Investment Research, "Catalyst's Firdapse is the company’s first approved product. The drug is the first FDA-approved treatment for Lambert-Eaton Myasthenic Syndrome (LEMS) in adults, which was approved in November 2018 and launched in January. The company generated entire first-quarter revenues from Firdapse. Catalyst is also developing Firdapse to treat additional rare neuromuscular diseases. However, all the other candidates in its portfolio are in early stages of development. Thus, the successful development and commercialization of drug candidates are highly crucial for the company. Shares of the company have outperformed the industry year to date. Estimates have remained stable ahead of the Q2 results. The company has a mixed record of earnings surprises in the recent quarters." (7/31/2019) 2. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and PT of $10 per share of CPRX. the FDA approved private company the treatment of LEMS in pts 6 to <17 years of age. This is the first drug approved for pediatric LEMS. However, Catalyst's slighty different salt form of amifampridine, marketed as Firdapse, was the first drug approved for LEMS, but for adults only. We were surprised by this announcement as no clinical studies were conducted in the pediatric population that we are aware of, and the approval relied on studies of the drug in adults with LEMS, including PK data that were then modeled/extrapolated to identify the dosing regimen in pediatric pts."" (5/7/2019) Has Catalyst Pharmaceuticals been receiving favorable news coverage? Headlines about CPRX stock have been trending extremely negative on Wednesday, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Catalyst Pharmaceuticals earned a media sentiment score of -5.0 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Catalyst Pharmaceuticals. Are investors shorting Catalyst Pharmaceuticals? Catalyst Pharmaceuticals saw a increase in short interest in February. As of February 14th, there was short interest totalling 12,690,000 shares, an increase of 12.1% from the January 30th total of 11,320,000 shares. Based on an average daily trading volume, of 2,330,000 shares, the days-to-cover ratio is presently 5.4 days. Currently, 13.3% of the shares of the company are sold short. View Catalyst Pharmaceuticals' Current Options Chain. Who are some of Catalyst Pharmaceuticals' key competitors? Some companies that are related to Catalyst Pharmaceuticals include Eidos Therapeutics (EIDX), Turning Point Therapeutics (TPTX), Ironwood Pharmaceuticals (IRWD), Ligand Pharmaceuticals (LGND), Tricida (TCDA), Esperion Therapeutics (ESPR), Arvinas (ARVN), BELLUS Health (BLUSF), Heron Therapeutics (HRTX), Aimmune Therapeutics (AIMT), Zymeworks (ZYME), IGM Biosciences (IGMS), Alder Biopharmaceuticals (ALDR), Akcea Therapeutics (AKCA) and Corcept Therapeutics (CORT). What other stocks do shareholders of Catalyst Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Pharmaceuticals investors own include Novavax (NVAX), Amarin (AMRN), Corbus Pharmaceuticals (CRBP), Inovio Pharmaceuticals (INO), Verastem (VSTM), AcelRx Pharmaceuticals (ACRX), Exelixis (EXEL), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX) and Cognex (CGNX). Who are Catalyst Pharmaceuticals' key executives? Catalyst Pharmaceuticals' management team includes the folowing people: Mr. Patrick J. McEnany, Co-Founder, Chairman, Pres & CEO (Age 72)Ms. Alicia Grande, VP, Treasurer & CFO (Age 48)Dr. Steven R. Miller, COO & Chief Scientific Officer (Age 57)Mr. Brian Elsbernd, Chief Legal & Compliance Officer (Age 55)Dr. Gary Ingenito, Chief Medical Officer & Head of Regulatory Affairs (Age 63) Who are Catalyst Pharmaceuticals' major shareholders? Catalyst Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include State Street Corp (7.20%), Goldman Sachs Group Inc. (1.87%), Prudential Financial Inc. (1.72%), Marshall Wace LLP (1.52%), Geode Capital Management LLC (1.46%) and AQR Capital Management LLC (1.10%). Company insiders that own Catalyst Pharmaceuticals stock include Charles B O'keeffe, Donald A Denkhaus, Gary Ingenito and Patrick J Mcenany. View Institutional Ownership Trends for Catalyst Pharmaceuticals. Which major investors are selling Catalyst Pharmaceuticals stock? CPRX stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, Chicago Equity Partners LLC, Panagora Asset Management Inc., Cadence Capital Management LLC, Bank of America Corp DE, Geode Capital Management LLC, UBS Asset Management Americas Inc. and Jefferies Group LLC. View Insider Buying and Selling for Catalyst Pharmaceuticals. Which major investors are buying Catalyst Pharmaceuticals stock? CPRX stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, Marshall Wace LLP, AQR Capital Management LLC, Goldman Sachs Group Inc., Royce & Associates LP, Prudential Financial Inc., Credit Suisse AG and Acadian Asset Management LLC. Company insiders that have bought Catalyst Pharmaceuticals stock in the last two years include Charles B O'keeffe, Donald A Denkhaus and Patrick J Mcenany. View Insider Buying and Selling for Catalyst Pharmaceuticals. How do I buy shares of Catalyst Pharmaceuticals? Shares of CPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Catalyst Pharmaceuticals' stock price today? One share of CPRX stock can currently be purchased for approximately $4.66. How big of a company is Catalyst Pharmaceuticals? Catalyst Pharmaceuticals has a market capitalization of $480.20 million and generates $500,000.00 in revenue each year. The biopharmaceutical company earns $-34,000,000.00 in net income (profit) each year or ($0.33) on an earnings per share basis. Catalyst Pharmaceuticals employs 51 workers across the globe.View Additional Information About Catalyst Pharmaceuticals. What is Catalyst Pharmaceuticals' official website? The official website for Catalyst Pharmaceuticals is http://www.catalystpharma.com/. How can I contact Catalyst Pharmaceuticals? Catalyst Pharmaceuticals' mailing address is 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134. The biopharmaceutical company can be reached via phone at 305-420-3200 or via email at [email protected] MarketBeat Community Rating for Catalyst Pharmaceuticals (NASDAQ CPRX)Community Ranking: 3.1 out of 5 ( )Outperform Votes: 418 (Vote Outperform)Underperform Votes: 259 (Vote Underperform)Total Votes: 677MarketBeat's community ratings are surveys of what our community members think about Catalyst Pharmaceuticals and other stocks. Vote "Outperform" if you believe CPRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CPRX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/26/2020 by MarketBeat.com StaffFeatured Article: What causes a recession?
